Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Obese Patients with Genetic Defects in the MC4R Pathway: 2-Stage Run-in and Randomized Withdrawal
2021-002855-12Phase 2Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Sep 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of setmelanotide in obesity (3 arms), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Clinically meaningful weight-related response in MC4R pathway defect obesity. Started Sep 2021; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on 2021-002855-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002855-12.